Journal Logo

Erratum

Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life: Erratum

doi: 10.1097/CAD.0000000000001029
  • Free

The authors of this paper [1] have provided a correction to the conflict of interest statement and acknowledge the following source of funding for the study: CNPq (National Council for Scientific and Technological Development, grant number 404425/2016-0).

Reference

1. Baldan Ferrari G, Coelho França Quintanilha J, Berlofa Visacri M, Oliveira Vaz C, Cursino MA, Sampaio Amaral L, et al. Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life. Anticancer Drugs. 2020; 31:523–527.
    Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.